ADGRL3 and breast cancer: Interestingly, although CL1 tumors show the most frequent activation of the RAS-MAPK pathway, it is noteworthy that the activation of this mitogenic pathway is also a common event in CL2 and CL3 tumors, compared with other breast cancer subtypes.